Wikipedia -WSS

Wikipedia

author：knowledge 2025-10-01 00:46:24 - browse：9464

inflamed intestine on a dark blue background — biotech coverage from STAT — Adobe

What happens after you close a nearly $11 billion acquisition?

Well, for Prometheus Therapeutics’ former CEO Mark McKenna, there was a brief vacation. But within weeks of the company’s acquisition by Merck closing last June, he was thinking about ideas for the future.

Investors were floating ideas by him. McKenna discussed possibilities with his teenagers and Prometheus’ chief scientific officer. This “summer of discovery,” as McKenna called it, brought him back to the immune system. Prometheus and some other companies have been able to capitalize on creating treatments for conditions like inflammatory bowel disease and psoriasis, while arthritis medications like Humira have brought in billions of dollars in sales. But the field hadn’t quite received the same attention as missions to cure cancer.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： U.K. officials, researchers try to ease path for bespoke genetic treatments

focus

WSS

Readout Newsletter: Illumina, CRISPR, Regeneron

In Spain, a hospital brews its own CAR

Prime Medicine, Myeloid Therapeutics clash over genome

Carvykti CAR

David Ricks of Eli Lilly: best biopharma CEO of 2023

Erich Jarvis studies song birds to learn about human stuttering

entertainment

Wikipedia

focus

Walensky prepares to leave CDC — and Congress — behind

With Wegovy coverage, Medicare patients may face high costs

Alkermes shareholders re

6 surprising facts about sugar

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Prime Medicine, Myeloid Therapeutics clash over genome

Continuity nursing helped my family in our darkest PICU moments

Steward Health Care expansion into Malta flopped

In Memoriam: Notable people who died in 2023

Prime Medicine, Myeloid Therapeutics clash over genome

hotspot

Adam's Take: Intra

Violet CEO on training clinicians to promote more inclusive care

Testing GLP

Readout LOUD podcast, live from the STAT Breakthrough Summit East

Asbestos ban is immediate, but health effects will linger for decades

'Patient friction coefficient' can gauge a clinical trial's patient burden

focus

explore

hotspot

knowledge